Walburga Engel-Riedel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Walburga Engel-Riedel has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Erich Stoelben
St-Hildegardis-Krankenhaus
2 shared publications - Assad Chemaissani
Cologne Metropolitan General Hospital, Clinic for Thoracic Disease, D-51109 Köln, Germany
1 shared publication - Frank Beckers
Department of Thoracic Surgery, University Medical Center Witten/Herdecke, Lung Clinic Merheim, Campus Cologne, Cologne, Germany
1 shared publication - Hans-Jörg Kraus
St. Marien-Krankenhaus, (Medical Education Hospital of the University of Marburg), Department of Radiotherapy, D-57072 Siegen, Germany
1 shared publication - Michael Brockmann
Kliniken der Stadt Köln, Klinikum der Privaten Universität Witten, Ostmerheimer Str. 200, 51109, Köln, (Cologne), Germany
1 shared publication - Oliver Schildgen
Kliniken Der Stadt Köln gGmbH, Institut Für Pathologie, Ostmerheimer Str. 200, Cologne, Germany
1 shared publication
Latest Publications
- Open Access
- 19 August 2014
- Published by Springer Nature in BMC Research Notes
- Vol. 7 (1) , 1-3
Absence of amplification of the FGFR1-gene in human malignant mesothelioma of the pleura: a pilot study
- 19 August 2014
- Published by Springer Nature in BMC Research Notes
- Vol. 7 (1) , 1-3
Open AccessAbsence of amplification of the FGFR1-gene in human malignant mesothelioma of the pleura: a pilot study
- Open Access
- 20 August 2006
- Published by Springer Nature in Radiation Oncology
- Vol. 1 (1) , 30
Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases
We prospectively reviewed response rates, local control, and side effects after non-fractionated stereotactic high single-dose body radiation therapy for lung tumors. Fifty-eight patients underwent radiosurgery involving single-dose irradiation. With 25 patients, 31 metastases in the lungs were irradiated; with each of 33 patients, stage I non-small cell lung cancer (NSCLC) was subject to irradiation. The standard dose prescribed to the isocenter was 30 Gy with an axial safety margin of 10 mm and a longitudinal safety margin of 15 mm. The planning target volume (PTV) was defined using three CT scans with reference to the phases of respiration so that the movement span of the clinical target volume (CTV) was enclosed. The volume of the metastases (CTV) varied from 2.8 to 55.8 cm3 (median: 6.0 cm3) and the PTV varied from 12.2 to 184.0 cm3 (median: 45.0 cm3). The metastases ranged from 0.7 to 4.5 cm in largest diameter. The volume of the bronchial carcinomas varied from 4.2 to 125.4 cm3 (median: 17.5 cm3) and the PTV from 15.6 to 387.3 cm3 (median: 99.8 cm3). The bronchial carcinomas ranged from 1.7 to 10 cm in largest diameter. Follow-up periods varied from 6.8 to 63 months (median: 22 months for metastases and 18 months for NSCLC). Local control was achieved with 94% of NSCLC and 87% of metastases. No serious symptomatic side effects were observed. According to the Kaplan-Meier method the overall survival probability rates of patients with lung metastases were as follows: 1 year: 97%, 2 years: 73%, 3 years: 42%, 4 years: 42%, 5 years: 42% (median survival: 26 months); of those with NSCLC: 1 year: 83%, 2 years: 63%, 3 years: 53%, 4 years: 39%: (median survival: 20.4 months). Non-fractionated single-dose irradiation of metastases in the lungs or of small, peripheral bronchial carcinomas is an effective and safe form of local treatment and might become a viable alternative to invasive techniques.
- 20 August 2006
- Published by Springer Nature in Radiation Oncology
- Vol. 1 (1) , 30
Open AccessStereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases
We prospectively reviewed response rates, local control, and side effects after non-fractionated stereotactic high single-dose body radiation therapy for lung tumors. Fifty-eight patients underwent radiosurgery involving single-dose irradiation. With 25 patients, 31 metastases in the lungs were irradiated; with each of 33 patients, stage I non-small cell lung cancer (NSCLC) was subject to irradiation. The standard dose prescribed to the isocenter was 30 Gy with an axial safety margin of 10 mm and a longitudinal safety margin of 15 mm. The planning target volume (PTV) was defined using three CT scans with reference to the phases of respiration so that the movement span of the clinical target volume (CTV) was enclosed. The volume of the metastases (CTV) varied from 2.8 to 55.8 cm3 (median: 6.0 cm3) and the PTV varied from 12.2 to 184.0 cm3 (median: 45.0 cm3). The metastases ranged from 0.7 to 4.5 cm in largest diameter. The volume of the bronchial carcinomas varied from 4.2 to 125.4 cm3 (median: 17.5 cm3) and the PTV from 15.6 to 387.3 cm3 (median: 99.8 cm3). The bronchial carcinomas ranged from 1.7 to 10 cm in largest diameter. Follow-up periods varied from 6.8 to 63 months (median: 22 months for metastases and 18 months for NSCLC). Local control was achieved with 94% of NSCLC and 87% of metastases. No serious symptomatic side effects were observed. According to the Kaplan-Meier method the overall survival probability rates of patients with lung metastases were as follows: 1 year: 97%, 2 years: 73%, 3 years: 42%, 4 years: 42%, 5 years: 42% (median survival: 26 months); of those with NSCLC: 1 year: 83%, 2 years: 63%, 3 years: 53%, 4 years: 39%: (median survival: 20.4 months). Non-fractionated single-dose irradiation of metastases in the lungs or of small, peripheral bronchial carcinomas is an effective and safe form of local treatment and might become a viable alternative to invasive techniques.